ArticleBioactive materials2022
Sprayable nanomicelle hydrogels and inflammatory bowel disease patient cell chips for development of intestinal lesion-specific therapy.
Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Bioadhesive hydrogels as immunomodulatory interfaces for chronic wound healing: from microenvironmental regulation mechanism to engineering strategies.Burns & trauma · 2026Review
- Gastrointestinal tract, its pathophysiology andWorld journal of gastroenterology · 2025Review
- Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions.RSC advances · 2025Review
- Gut-directed therapeutics in inflammatory bowel disease.Current opinion in gastroenterology · 2025Review
- Review
- Recent Advances in the Application of Hydrogels as Drug Carriers in Inflammatory Bowel Disease: A Review.International journal of molecular sciences · 2025Review
- Intestinal organ chips for disease modelling and personalized medicine.Nature reviews. Gastroenterology & hepatology · 2024Review
- Inhibition of Angiogenesis and Effect on Inflammatory Bowel Disease of Ginsenoside Rg3-Loaded Thermosensitive Hydrogel.Pharmaceutics · 2024Article
- Stimulus-Responsive Hydrogels as Drug Delivery Systems for Inflammation Targeted Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Intestinal Membrane Function in Inflammatory Bowel Disease.Pharmaceutics · 2023Review
- A Mechanically Resilient and Tissue-Conformable Hydrogel with Hemostatic and Antibacterial Capabilities for Wound Care.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Body-Shaping Membrane to Regenerate Breast Fat by Elastic Structural Holding.Research (Washington, D.C.) · 2023Article
- Pretreatment with IPA ameliorates colitis in mice: Colon transcriptome and fecal 16S amplicon profiling.Frontiers in immunology · 2022Article
- Gut-on-a-chip for disease models.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
All-in-one treatments represent a paradigm shift in future medicine. For example, inflammatory bowel disease (IBD) is mainly diagnosed by endoscopy, which could be applied for not only on-site monitoring but also the intestinal lesion-targeted spray of injectable hydrogels. Furthermore, molecular conjugation to the hydrogels would program both lesion-specific adhesion and drug-free therapy. This study validated this concept of all-in-one treatment by first utilizing a well-known injectable hydrogel that underwent efficient solution-to-gel transition and nanomicelle formation as a translatable component. These properties enabled spraying of the hydrogel onto the intestinal walls during endoscopy. Next, peptide conjugation to the hydrogel guided endoscopic monitoring of IBD progress upon adhesive gelation with subsequent moisturization of inflammatory lesions, specifically by nanomicelles. The peptide was designed to mimic the major component that mediates intestinal interaction with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.